Ab1672 #ACR22 SSc on Women's Health 100 pts - 75% lSSc 59% sexuality aff by SSc (vag dryness 67%, dig ulcers 37%, GI 37%, dyspnea 20%) 48 pts dx during repro ys - 73% never discuss contraception, 30% didn't reach family plan 22 pt - 43 pregn, 33 birth: C-sxn, low bth wt @Rheumnow https://t.co/JRkyCVEXLB

More than 25,000 #ACR22 tweets since November 1 - keep going strong today and we will reach 100,000,000 impressions. Congrats to @rheum_cat, @RheumNow and @CreakyJoints for having the most impact with over 10M impressions each. @ACRheum @StevenEchard https://t.co/K2Kr4sAicS

Sometimes your RA pts are eligible for ICI cancer immunotherapy, but there’s hesitancy because of autoimmune risk/bad irAEs @DanaFarber @MassGenBrigham: more RA flares but similar mortality, severe irAEs rates Give them what they need! ABST1667 @jeffsparks #ACR22 @RheumNow https://t.co/WdDP8IeIYG

Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients and improvement in quality of life. Sustained remission was 28.3% SAR vs 10.3% comparator arm. Spiera R Abs#1676 https://t.co/gXGJzbYLHK #ACR22 @RheumNow https://t.co/oZBsRtxMUw

Very interesting Thieves Market case... which I have also seen! Don't forget mycoplasma pneumoniae-induced rash and mucositis (MIRM) when patients presen tw/oral ulceration My patient had +ANA and carried a dx of PFAPA; only responded to abx! #ACR22 @RheumNow ABSTR#TMO2 https://t.co/B9dBkZyrlN

What's your view look like? Are you in-person or virtual? Share a picture from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/DE7HhDzyJY

#abst1679 #acr22 @rheumnow CARRA STOP-JIA early introduction of bDMARD beneficial in polyarticular JIA: in early combination of cDMARD+biologic group > pts able to achieve Clinical Remission& significantly longer T spent in CID& cJADAS10 ID during the 3 year study vs step up Rx https://t.co/xwQJnSeCNE

Promising data on denosumab in erosive OA Phase 2 study - less erosive progression, more symptom improvement Abs# L05 @RheumNow #ACR22 https://t.co/9Fg3r02ZQG

Wittoek et al. 48-week RCT of Denosumab in erosive hand OA. Prevents structural progression! @RheumNow #ACR22 Abstr#L05 #ACRbest https://t.co/CI6VBERSmn https://t.co/OszJkGeJF7

L05 #ACR22 High-dose Denosumab in Erosive Hand OA 48Wk, Double-blind PBO Phase 2 100 patients GUSS change higher in DEN v PBO at w24, incr at w48 New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001) Open label extension w improvement to baseline @RheumNow https://t.co/X6MF9q2bKj